Vaxxinity, Inc. (VAXX)

0.1700 -0.0200 (-10.53%) 收市：03:22PM EDT

Vaxxinity, Inc.

505 Odyssey Way
Merritt Island, FL 32953
United States
(254)244-5739
https://www.vaxxinity.com

版塊: Healthcare
行業: Biotechnology
全職員工: 57

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Louis Garfield Reese IV	Co-Founder & Executive Chairman of the Board	275.57k	無	1982
Ms. Mei Mei Hu J.D.	Co-Founder, President, CEO & Director	345.14k	無	1983
Ms. Sumita Ray J.D.	Chief Legal, Compliance & Administrative Officer and Corporate Secretary	465.56k	無	1974
Mr. Jason Pesile CPA, M.B.A.	Chief Accounting Officer	無	無	1973
Dr. Jean-Cosme Dodart Ph.D.	Chief Scientific Officer	無	無	無
Mr. Mark Joinnides MSE	Chief of Staff	無	無	無
Dr. Manal Morsy M.B.A., M.D., PH.D.	Chief Regulatory Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

公司管治

截至 2024年6月1日 止，Vaxxinity, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：8；股東權利：10；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。